The future of antibody therapy in Chronic Lymphocytic Leukemia

2021 ◽  
Author(s):  
Jennifer L. Crombie ◽  
Jennifer R. Brown
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Antibody Therapy ◽  
Lymphocytic Leukemia ◽  
The Future

Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?

2014 ◽  
Vol 15 (7) ◽  
pp. 897-900 ◽  
Author(s):  
Gillian G Johnson ◽  
Daniel F Carr ◽  
Munir Pirmohamed ◽  
Andrew R Pettitt
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
The Future

Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?

2016 ◽  
Vol 9 (7) ◽  
pp. 679-693 ◽  
Author(s):  
Anna Maria Frustaci ◽  
Marco Montillo ◽  
Paola Picardi ◽  
Maddalena Mazzucchelli ◽  
Roberto Cairoli ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Standard Chemotherapy ◽  
New Agents ◽  
The Future ◽  
Treatment Paradigm ◽  
The Way

scholarly journals Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia

Blood ◽  
1982 ◽  
Vol 59 (5) ◽  
pp. 1036-1045 ◽  
Author(s):  
RO Dillman ◽  
DL Shawler ◽  
RE Sobol ◽  
HA Collins ◽  
JC Beauregard ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Lymphocytic Leukemia ◽  
Cell Injury ◽  
Antibody Therapy ◽  
Lymphocytic Leukemia ◽  
Murine Monoclonal Antibody ◽  
Rapid Infusion ◽  
Experimental Trials ◽  
Free Serum

We infused the murine monoclonal antibody T101 into two patients with advanced refractory chronic lymphocytic leukemia (CLL) after confirming its reactivity with their CLL cells. One patient received doses of 1, 3, and 12 mg; the second patient received 10 mg. Antibody was delivered over 10--15 min. The major observations were: (1) T101 murine monoclonal antibody did bind to cells with T65 surface antigen and saturated these cells in vivo; (2) cells that bound T101 disappeared from the circulation by 2 hr after treatment, as evidenced by a marked drop in lymphocyte counts; (3) T101 serotherapy resulted in some intravascular cell injury associated with sequestration and probably destruction in the liver and lung; (4) free serum T101 was demonstrable, but disappeared by 2--4 hr after infusion; (5) rapid infusion of T101 did not induce significant modulation of T65; (6) rapid infusion of greater than 10 mg of T101 was associated with significant systemic reactions. Monoclonal antibodies may someday have an application in leukemia therapy, but additional experimental trials are clearly indicated.

Sign in / Sign up

Export Citation Format

Share Document